So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

Entresto is already approved to treat heart failure with reduced ejection fraction (HFrEF), caused by the heart muscles not pumping effectively, and has revitalised the treatment of patients with ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto ...

Novartis, an innovative medicines company, announced that the company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that ...

MSN's version of Entresto was approved by the U.S. Food and Drug Administration last year. Novartis sued MSN and others seeking to launch Entresto generics for patent infringement. The U.S. Court ...

An attorney for MSN declined to comment. India-based MSN's version of Entresto was approved by the U.S. Food and Drug Administration last year. Novartis sued MSN and others seeking to launch ...

MSN's version of Entresto was approved by the US Food and Drug Administration last year. Novartis sued MSN and others seeking to launch Entresto generics for patent infringement. The US Court of ...